|
WO2021040519A1
|
|
Inhibition of mycobacterial type vii secretion
|
|
WO2020197399A1
|
|
Methods and means for stratification of an individual suffering from, or suspected to suffer from, a progressive neurodegenerative disease
|
|
WO2020022891A2
|
|
Biomarkers for atrial fibrillation
|
|
WO2020013693A1
|
|
Urine dna methylation markers for bladder cancer
|
|
WO2019039937A1
|
|
Therapeutic combination for cancer treatment
|
|
WO2019022605A1
|
|
Micro rna-based methods and compositions for detection of hpv-induced invasive cancers, and their high-grade precursor lesions
|
|
CA3062255A1
|
|
Therapeutic effects of guanabenz treatment in vanishing white matter
|
|
WO2018151601A1
|
|
Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
|
|
WO2018111099A1
|
|
Biomarkers and treatments for cerebral amyloid angiopathy (caa)
|
|
EP3494128A1
|
|
Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon
|
|
EP3445384A1
|
|
Means and methods for treating diastolic dysfunction in a subject
|
|
NL2017203B1
|
|
Surgical instrument
|
|
AU2015252223A1
|
|
Small ncRNAs as biomarkers
|
|
AU2011277178A1
|
|
A method of analysing a blood sample of a subject for the presence of a disease marker
|
|
EP2201567A1
|
|
Noise suppression in speech signals
|
